Fountain Life operates four longevity centers in the U.S., including two in Florida (Naples and Lake Nona-Orlando), with an additional location set to open soon in Miami.

Celularity says it develops cell therapies ethically sourced from postpartum placenta tissues. Its product pipeline includes human placental-derived stem cells and mesenchymal stem cell-like product candidates, supported by clinical datasets consistent with the conditions outlined in Florida’s legislation.

Robert J. Hariri, M.D., Ph.D., CEO and Chairman of Celularity, stated, “Celularity’s ability today to supply clinical-grade, ethically-sourced stem cells ensures ‘Day One’ readiness under the new Florida law to partners like Fountain Life. We applaud Florida’s proactive, data-driven approach to advancing investigational stem cell therapies and improving patient outcomes, for which Fountain Life, a leading science-backed longevity center, powered by AI, is an ideal partner.” Hariri added, “Celularity is unique in our ability to also deliver placental-derived biomaterials for many of the indications targeted in the Florida legislation and we are committed to meeting the high standards laid out in this important new healthcare law.”